Archive for the ‘AnaptysBio Inc’ Category

AnaptysBio Inc

October 1st, 2015 | Posted in 2015, AnaptysBio Inc

AnaptysBio Inc, San Diego, filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed IPO. AnaptysBio develops antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology.


August 19th, 2015 | Posted in 2015, AnaptysBio Inc

AnaptysBio, San Diego, has completed a $40 Million Series D round of financing. The funding will advance the company’s receptor antibody programs through key Phase 2 studies. It will also support the continued discovery of therapeutic antibodies against emerging target biology in inflammational immuno-oncology, using AnaptysBio’s proprietary antibody discovery platform.


April 22nd, 2014 | Posted in 2014, AnaptysBio Inc

AnaptysBio, San Diego, could receive up to $324 million under an agreement for the development of cancer drugs. AnaptysBio is partnering in 3 programs with Mass-based, Tesaro. The targeted drugs are antibodies meant to activate immune system response “chekcpoints”. In addition to milestone payments, the privately-held company will received royalties on drugs that come to […]